Johnson & Johnson Q3
This article was originally published in The Rose Sheet
Executive Summary
Worldwide skin care sales advance 15% to $390 mil. in third quarter, led by Neutrogena, Aveeno, Clean & Clear brands, firm says in 1Oct. 15 sales and earnings release. Skin care sales in the U.S. rose 13% to $170 mil. and were up 17% to $169 mil. in international markets. "Continued strength of the overall product line, momentum associated with a broad range of new product offerings launched earlier this year and expanded growth of these equities outside the U.S. were the key drivers" of growth, according to J&J. Baby and kids care sales rose 4% worldwide to $300 mil., reflecting strong sales outside the U.S. of skin care and wipes products. Domestic baby care sales declined 3% to $68 mil., depressed by divestiture of Healthflow and Sippy Cup businesses...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.